Introduction
Epigenetic events, defined as mitotically and meiotically heritable changes in gene expression that are not due to alteration in primary DNA sequence (1) , play important roles in carcinogenesis and tumor progression (2) . DNA cytosine methylation, post-translational modifications of core histones, and microRNA pathway constitute three major mechanisms of epigenetic regulation. Global DNA hypomethylation and promoter DNA hypermethylation are known to occur in human tumors, where promoter cytosine methylation inhibits gene expression and results in long-term gene silencing (2) .
Cytosine methylation pattern is maintained during cell division by DNA (cytosine-5)-methyltransferase 1 (DNMT1), and DNA methylation inhibitors were the first epigenetic drugs used for cancer treatment (3). 5-Azacytidine (5-Aza-CR) and 5-aza-2'-deoxycytidine (5-AzaCdR) are among the many cytosine nucleoside analogs that can inhibit DNA methylation and induce cellular differentiation (4) . These nucleoside analogs are incorporated into DNA of tumor cells during DNA replication and 5-azacytosine in DNA can bind to the cysteine residue at the active site of DNMTs (5) . This covalent and irreversible binding of the enzyme to drugsubstituted DNA is believed to be the principal mechanism of cytotoxicity (5), though it was also found that 5-Aza-CdR treatment could lead to the proteasomal degradation of DNMT1 independent of its catalytic cysteine residue (6). 5-Aza-CR and 5-Aza-CdR have been approved by FDA for the treatment of myelodysplastic syndromes and are widely studied for the treatment of hematological diseases (7) , including acute and chronic myeloid leukemia (AML and CML) (8) . However, the detailed mechanisms underlying the cytotoxic effects of these drugs, particularly which target gene(s) becomes epigenetically reactivated and results in the growth inhibition of leukemic cells, remain poorly defined.
To exploit the molecular mechanisms contributing to the anticancer activity of 5-AzaCdR in leukemia cells, we employed LC-MS/MS together with stable isotope labeling by amino acid in cell culture (SILAC) to assess, at the global proteome scale, the perturbation in protein expression of Jurkat-T human leukemia cells upon 5-Aza-CdR treatment. In this context, SILAC is a simple and efficient metabolic isotope-labeling method; when combined with LC-MS/MS analysis, the method can afford accurate quantification of subtle changes of protein abundance in the whole proteome (9) . With this method, we quantified more than 2780 unique proteins, 188 of which were significantly altered upon 5-Aza-CdR treatment. Importantly, the quantitative proteomic experiment revealed the 5-Aza-CdR-induced down-regulation of two essential enzymes in cholesterol biosynthesis, namely, farnesyl diphosphate synthase (FDPS) and farnesyl diphosphate farnesyltransferase (FDFT1, a.k.a. squalene synthase). This finding, along with follow-up studies allowed us to discover, for the first time, that 5-Aza-CdR exerts its cytotoxic effect via modulating cholesterol biosynthesis in leukemia and melanoma cells, which involves epigenetic reactivation of DPP4 gene.
Materials and Methods

Cell culture
All reagents unless otherwise stated were from Sigma, and all cell lines were obtained from ATCC (Manassas, VA). Jurkat-T, HL60 and K562 cells were cultured in Iscove's modified minimal essential medium (IMEM) supplemented with 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA), 100 IU/mL penicillin and 100 µg/mL streptomycin in 75 cm 2 (Invitrogen), to the lysine, arginine-depleted medium. The Jurkat-T cells were cultured in heavy IMEM medium for at least 10 days to achieve complete stable isotope incorporation.
5-Aza-CdR treatment and sample preparation
Jurkat-T cells, at a density of ~ 7×10 5 cells per mL in light or heavy IMEM medium, were treated with 5 μM 5-Aza-CdR for 24 hr. After treatment, the light and heavy cells were harvested by centrifugation at 300× g at 4°C for 5 min, and washed for three times with ice-cold PBS to remove culture medium and FBS. Cells were lysed with CelLytic TM M lysis buffer supplemented with 1 mM PMSF and a protease inhibitor cocktail. The resulting cell lysate was centrifuged at 16,000× g at 4°C for 30 min and supernatant collected. The protein concentration in the cell lysate was measured using Quick Start TM Bradford Protein Assay (Bio-Rad, Hercules, CA). In forward SILAC, the lysate of light labeled, drug-treated cells and that of the heavy labeled control cells were combined at 1:1 ratio (w/w), whereas the heavy labeled, drug-treated cell lysate was mixed equally with the light labeled, control lysate in the reverse SILAC experiment (Figure 1a ).
SDS-PAGE separation and in-gel digestion
The above equi-mass mixture of light and heavy lysates was separated on a 12% SDS-PAGE with a 4% stacking gel and stained with Coomassie blue. The gel was cut into 20 slices, and the proteins in individual gel slices were separately reduced in-gel with dithiothreitol (DTT) and alkylated with iodoacetamide (IAM). The proteins were subsequently digested at 37°C with trypsin (Promega, Madison, WI) for overnight. Following digestion, peptides were extracted from gels with 5% acetic acid in H 2 O and then with 5% acetic acid in CH 3 CN/H 2 O (1:1, v/v).
The resulting peptide mixtures were dried and stored at -80°C until further analysis.
LC-MS/MS for protein identification and quantification
On-line LC-MS/MS analysis was performed on an LTQ-Orbitrap Velos mass spectrometer coupled with an EASY n-LCII HPLC system and a nanoelectrospray ionization source (Thermo, San Jose, CA). The sample injection, enrichment, desalting, and HPLC separation were conducted automatically on a homemade trapping column (150 µm×50 mm) and a separation column (75 µm×120 mm, packed with ReproSil-Pur C18-AQ resin, 5 µm in particle size and 300 Å in pore size, Dr. Maisch HPLC GmbH, Germany). The peptide mixture was first loaded onto the trapping column with a solvent mixture of 0.1% formic acid in CH 3 CN/H 2 O (2:98, v/v) at a flow rate of 3.0 µL/min. The peptides were then separated using a 120-min linear gradient of 2-40% acetonitrile in 0.1% formic acid at a flow rate of 300 nL/min.
The LTQ-Orbitrap Velos mass spectrometer was operated in the positive-ion mode, and the spray voltage was 1.8 kV. All MS/MS spectra were acquired in a data-dependent scan mode, where one full-MS scan was followed with twenty MS/MS scans. The full-scan MS spectra (from m/z 350 to 2000) were acquired with a resolution of 60,000 at m/z 400 after accumulation to a target value of 500,000. The twenty most abundant ions found in MS at a threshold above 500 counts were selected for fragmentation by collision-induced dissociation at a normalized collision energy of 35%.
Data processing
The LC-MS/MS data were employed for the identification and quantification of global proteome, which were conducted using Maxquant, Version 1.2.0.18 (10) against IPI database (11), version 3.68 with 87,061 entries to which contaminants and reverse sequences were added.
The maximum number of miss-cleavages for trypsin was two per peptide. Cysteine carbamidomethylation and methionine oxidation were set as fixed and variable modifications, respectively. The tolerances in mass accuracy for MS and MS/MS were 25 ppm and 0.6 Da, respectively. Only those proteins with at least two distinct peptides being discovered from LC-MS/MS analyses were considered reliably identified. The protein expression ratio reported in the present study represented the normalized ratios determined by Maxquant, where the expression levels of the majority of proteins were assumed to be unchanged upon 5-Aza-CdR treatment and the median of log-transformed ratios of all quantified proteins was considered to be zero (12) .
The required false positive rate was set to 1% at the both peptide and protein levels, with the minimal required peptide length being set at 6 amino acids. The quantification was based on three independent SILAC and LC-MS/MS experiments, which included two forward and one reverse SILAC labelings. Only those proteins with alteration in expression levels being greater than 1.5 or less than 0.67 fold, and with quantification results from at least 2 sets (including both forward and reverse) of SILAC labeling experiments were considered significantly changed.
Exogenous cholesterol addition and cell viability assay
The cholesterol-BSA complex was prepared following a previously published method (13) . Briefly, a 10-ml aliquot of 1% cholesterol in ethanol was mixed with an equal volume of doubly distilled water under continuous stirring at room temperature. The milk-like solution was then centrifuged at 2,000× g for 10 min. The supernatant was discarded, and the pellet was resuspended in a 10-mL solution containing 0.25 M sucrose and 1 mM EDTA (pH 7. . After a 48-hr incubation, the cells were harvested by using trypsin-EDTA solution followed by centrifugation at 2,000 rpm at 4°C for 5 min and subsequently washed twice with PBS.
Western blot
Lysate of control and 5-Aza-CdR-treated Jurkat-T and K562 cells, along with that of DPP4 siRNA-treated WM-266-4 cells, were prepared following the above-described procedures.
After SDS-PAGE separation, proteins were transferred to a nitrocellulose membrane using a solution containing 10 mM NaHCO 3 , 3 mM Na 2 CO 3 , and 20% methanol. The membranes were blocked with 5% non-fat milk in PBS buffer containing 0.1% (v/v) Tween-20 (pH 7.5) for 7 hr and incubated overnight at 4°C with rabbit anti-FDPS antibody (1:400 dilution, Abgent, San Diego, CA) and rabbit anti-FDFT1 antibody (1:400 dilution) (Abgent). The membranes were washed with fresh PBS-T at room temperature for five times (10 min each). After washing, the membranes were incubated with HRP-conjugated secondary antibody (1:1000 dilution) at room temperature for 1 hr. The membranes were subsequently washed with PBS-T for five times. The secondary antibody was detected by using ECL Advance Western Blotting Detection Kit (GE Healthcare) and visualized with Hyblot CL autoradiography film (Denville Scientific, Inc., Metuchen, NJ). Intensities for immunoreactive bands were quantified using ImageJ (National Institutes of Health).
Results and Discussion
5-Aza-CdR treatment and protein quantification
It is widely accepted that treatment of cells with 5-Aza-CdR could lead to the incorporation of the modified nucleoside into cellular DNA, which traps covalently the DNMTs thereby inducing DNA hypomethylation (5). However, the target gene(s), whose reactivation gives rise to the cytotoxic effect of the drug, remains to be identified. To explore the molecular targets of 5-Aza-CdR, we employed an unbiased quantitative proteomic approach to identify, at the entire proteome scale, the drug-induced perturbation of protein expression in Jurkat-T cells.
To this end, we first established the optimal dose of 5-Aza-CdR by examining the survival rate LC-MS/MS allowed for the identification of a total of 3100 proteins in both forward and reverse SILAC experiments, and ~ 2780 of them were quantified (Figure 1b) . Details of all quantified proteins are listed in supplemental Table S1 . The distribution of changes in protein expression levels arising from 5-Aza-CdR treatment is displayed in Figure 1b . By using a ratio of >1.5 or <0.67 as threshold for the significantly changed proteins, 188 exhibited significant changes with at least 2 peptides being identified in at least two sets of SILAC labeling experiments (Table S2 ). Figure 2 depicts the representative ESI-MS results for two tryptic peptides derived from farnesyl diphosphate synthase (FDPS), which reveals the 5-Aza-CdRinduced down-regulation of this protein. We next performed protein interaction network and pathway analysis using the Ingenuity Pathway Analysis (IPA) software (17) . Proteins exhibiting greater than a 1.5-fold change in expression upon the drug treatment were considered for the analysis. Networks represent a highly interconnected set of proteins derived from the input dataset. Biological functions and processes were assigned to networks by mapping the proteins in the network to functions in the Ingenuity ontology. Several pathways were found to be altered included steroid (cholesterol) biosynthesis, granzyme signaling, mitochondria dysfunction, etc. (Table S3 ). 
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5-Aza-CdR-induced inhibition of cholesterol biosynthesis involves epigenetic reactivation of
DPP4 gene
Viewing that 5-Aza-CdR treatment can lead to cytosine demethylation and reactivation of epigenetically silenced genes, we surveyed literature for mammalian genes that are both epigenetically silenced in leukemia cells and involved in cholesterol biosynthesis. We found that dipeptidyl peptidase 4 (DPP4, a.k.a. CD26 in T cells or adenosine deaminase complexing protein)
is the only known human gene satisfying both criteria. In this regard, DPP4 was found to be epigenetically silenced in primary leukocytes isolated from adult T-lineage leukemic patients and in cultured human leukemia cells (27) . In addition, promoter cytosine methylation of DPP4 gene was observed to correlate positively with plasma HDL-cholesterol level in severely obese patients with metabolic syndrome (28) . Although our proteomic experiment did not allow us to identify or quantify the DPP4 protein (likely due to its low level of expression in Jurkat-T cells), real-time PCR experiment showed that 5-Aza-CdR treatment led to the reactivation of DPP4 gene in all three leukemia cell lines tested ( Figure S2 ).
Apart from leukemia cells, DPP4 is known to be epigenetically silenced in human melanoma cells (29) . We found that 5-Aza-CdR treatment also resulted in elevated expression of DPP4 ( Figure S2 ) and diminished endogenous cholesterol biosynthesis (Figure 3d Future experiments will be needed for understanding how reactivation of DPP4 gene leads to diminished levels of FDPS and FDFT1 proteins. In this vein, it is unlikely for these two enzymes to be direct substrates for DPP4 considering that the N-termini of neither proteins carry a DPP4 recognition site and DPP4 was found to be incapable of cleaving large protein molecules (31) .
It is worth emphasizing the advantage of the quantitative proteomic method for discovering molecular mechanisms of action of anti-cancer drugs. The most notable outcome of the unbiased quantitative proteomic approach is perhaps the generation of novel hypotheses.
Prior to this work, few would have thought that epigenetic reactivation of DPP4 gene and the resulting inhibition in cholesterol biosynthesis would constitute an important molecular mechanism contributing to the anti-leukemic effect of 5-Aza-CdR. Now, this becomes evident on the basis of the validation experiments. The ability to discover molecular target of 5-Aza-CdR that lies outside of previous biological knowledge is a major motivation for the use of unbiased proteome-wide approaches for unraveling novel mechanisms of action of anti-neoplastic agents and is well supported by the results generated from the present study. It is also worth noting that 5-Aza-CdR treatment did not give rise to significant decreases in expression of FDPS and FDFT1 at the mRNA level ( Figure 6 ); likewise, treatment with DPP4 siRNA did not lead to elevated mRNA expression of these two genes in WM-266-4 cells ( Figure S3 ), revealing the lack of transcriptional regulation of these two genes by DPP4. Therefore, this result also underscored that the new pathway uncovered from quantitative proteomic strategy would not be discovered with the conventional microarray-based approach.
In conclusion, the current study uncovered a novel mechanism of 5-Aza-CdR-induced anticancer effect. In the future, it will be important to assess whether the findings made with 
